Selected article for: "disease severity and gene expression"

Author: Sposito, Benedetta; Broggi, Achille; Pandolfi, Laura; Crotta, Stefania; Ferrarese, Roberto; Sisti, Sofia; Clementi, Nicola; Ambrosi, Alessandro; Liu, Enju; Frangipane, Vanessa; Saracino, Laura; Marongiu, Laura; Facchini, Fabio A; Bottazzi, Andrea; Fossali, Tommaso; Colombo, Riccardo; Clementi, Massimo; Tagliabue, Elena; Pontiroli, Antonio E; Meloni, Federica; Wack, Andreas; Mancini, Nicasio; Zanoni, Ivan
Title: Severity of SARS-CoV-2 infection as a function of the interferon landscape across the respiratory tract of COVID-19 patients.
  • Cord-id: rvm93xv9
  • Document date: 2021_3_30
  • ID: rvm93xv9
    Snippet: The COVID-19 outbreak driven by SARS-CoV-2 has caused more than 2.5 million deaths globally, with the most severe cases characterized by over-exuberant production of immune-mediators, the nature of which is not fully understood. Interferons of the type I (IFN-I) or type III (IFN-III) families are potent antivirals, but their role in COVID-19 remains debated. Our analysis of gene and protein expression along the respiratory tract shows that IFNs, especially IFN-III, are over-represented in the lo
    Document: The COVID-19 outbreak driven by SARS-CoV-2 has caused more than 2.5 million deaths globally, with the most severe cases characterized by over-exuberant production of immune-mediators, the nature of which is not fully understood. Interferons of the type I (IFN-I) or type III (IFN-III) families are potent antivirals, but their role in COVID-19 remains debated. Our analysis of gene and protein expression along the respiratory tract shows that IFNs, especially IFN-III, are over-represented in the lower airways of patients with severe COVID-19, while high levels of IFN-III, and to a lesser extent IFN-I, characterize the upper airways of patients with high viral burden but reduced disease risk or severity; also, IFN expression varies with abundance of the cell types that produce them. Our data point to a dynamic process of inter- and intra-family production of IFNs in COVID-19, and suggest that IFNs play opposing roles at distinct anatomical sites.

    Search related documents:
    Co phrase search for related documents
    • abortive infection and acid inducible gene: 1
    • abortive infection and acute ards respiratory distress syndrome: 1
    • abortive infection and lung pathology: 1
    • acid inducible and additional study: 1
    • acid inducible and lung viral infection: 1
    • acid inducible gene and additional study: 1
    • acid inducible gene and lung viral infection: 1
    • acute ards respiratory distress syndrome and additional study: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and administration production: 1
    • acute ards respiratory distress syndrome and local level: 1, 2
    • acute ards respiratory distress syndrome and local production: 1, 2
    • acute ards respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute ards respiratory distress syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute ards respiratory distress syndrome and low airway: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • acute ards respiratory distress syndrome and low respiratory tract: 1, 2
    • acute ards respiratory distress syndrome and lung barrier: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute ards respiratory distress syndrome and lung barrier function: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29